• Cybersecurity services and technology provider SideChannel Inc. is a provider of expert “virtual” chief information security officer (“vCISO”) guidance to SMBs that can’t sustain a full-time CISO as part of their staff budget
• The need for CISO guidance is apparent in the trillions of dollars lost worldwide to cyber attacks on a yearly basis and the ever-evolving nature of cyber attack threats
• SideChannel also provides a microsegmentation software-as-a-service (“SaaS”), branded Enclave, that is available to clients via subscription or as a managed service offering, to help strengthen company computer systems against invasive attacks
• SideChannel is celebrating its ability to retain its clientele revenue on an ongoing year-to-year trailing basis, the company’s CFO stated in a recent company webcast

As companies assess their security needs to avoid severe damage to their budget line and reputation, cybersecurity needs are taking on an ever greater emphasis. An estimated 30,000 websites are hacked daily, with the cost of cyber attacks placed at $6 trillion last year, underlining the reality of a malicious environment for business activities online (https://ibn.fm/fR7i8).

While businesses routinely are identifying cyber threats to their operations, a serious question they need to ask themselves is just how many threats are currently undetected, as risk management company C2’s CEO Jonathan Wood recently noted in a CPO Magazine article. It’s important to consider that many cybercriminals will breach a company’s infrastructure, and then lurk in the shadows until the most opportune moment arises for launching a full-scale attack (https://ibn.fm/FIKiC).

Detecting hidden cyber threats can be complicated and easily overlooked until they strike and damage is done.

“We’re seeing attacks increase. We’re seeing the costs of these attacks increase over time. And we’re seeing (the nature of the attacks) change,” SideChannel (OTCQB: SDCH) CEO Brian Haugli stated in a live company webcast recently.

SideChannel is a cybersecurity services and technology provider whose key service is providing virtual chief information security officers (“vCISOs”) on contract to small and medium-sized businesses (“SMBs”) that don’t have a budget capacity to hire their own full-time CISOs.

“Our revenue is really built on relationships,” CFO Ryan Polk added during the webcast (https://ibn.fm/MWldH). “The vast majority of the work that we do for our clients has an ongoing nature to it. … We are retaining about 73 percent on a trailing 12-month basis of the revenue that we generated one year ago.”

Although vCISOs might be described somewhat dismissively as rent-a-CISOs, SideChannel’s cybersecurity experts are presented to clients as guidance providers who can work in the boardroom alongside the companies’ leading officers.

“The cybersecurity profession is now akin to legal, and accounting, and insurance,” Haugli said during the webcast. “When we look inside organizations at the enterprise level we see the CISO right there with HR (Human Resources), and GC (General Contracting), and Internal Audit and other C-suite members for a reason. Because that’s how important it is for that organization’s success to address cybersecurity as an operational risk at an enterprise level. And our clients are seeing it, and they’re realizing the value that they’re getting out of it by working with us.”

SideChannel also has developed a microsegmentation security product named Enclave that it offers either as a software-as-a-service (“SaaS”) tool on a subscription basis, or as a managed service offering that exceeds what is otherwise available throughout the industry.

“Our (product) focus right now is to continue Enclave development and the roadmap we’ve built out for that,” Haugli said. “We are looking at new features around protecting endpoint devices with a more cloud-based and scalable capability. So we’re going to continue to develop around Enclave, adding new features and capabilities that make sense for how Enclave is structured — based … on what we’re seeing in our clients, what we’re hearing from our CISOs and what types of attacks or attack surface is out there.”

For more information, visit the company’s website at www.SideChannel.com.

NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

• Lexaria Bioscience is a global innovator in drug delivery platforms
• The company has been developing and commercializing patented DehydraTECH(TM), a technology that has been shown to increase the bioavailability of fat-soluble active molecules, improve the speed of onset and provide other benefits across multiple applications
• Lexaria has undertaken numerous R&D programs in an effort to build relationships with prospective corporate partners to out-license the technology or to form other profitable corporate relationships
• The company owes its achievements to its focus on R&D and the guidance provided by its highly experienced leadership, including CEO Chris Bunka, President John Docherty, as well as a dedicated and active board of directors

Lexaria Bioscience’s (NASDAQ: LEXX) path to becoming a global leader and innovator in drug delivery traces its origins to 2014, when CEO Chris Bunka redirected the company to its current business, focusing on the research and development (“R&D”) of the delivery of lipophilic active molecules based on its patented DehydraTECH(TM) technology. Protected by 28 granted patents worldwide, with many more pending around the world, the technology can lay claim to the potential of disrupting the drug delivery space as it is known today.

Typically, a drug delivery system is a formulation or a device that enables the introduction of a therapeutic substance into the body. It is specifically designed to improve the substance’s efficacy and safety by controlling the rate, time, and place of release of drugs in the body. Over the years, drug delivery scientists have been on a quest to improve the existing systems, leading to the introduction of nanoparticles, emulsifiers, and microalgae-based oral microcarriers (https://ibn.fm/V9lDo), just to name a few.

This quest is informed in large part by the shortcomings of existing systems. And as Lexaria has established, these systems are not particularly effective at delivering as much of the drug as possible into the bloodstream for use by the body; to put it more technically, they have low bioavailability. Additionally, the company has observed that drugs, especially fat-soluble active pharmaceutical ingredients (“APIs”), take a considerable time to start working when delivered using the existing systems.

In light of the evident shortcomings, Lexaria has been developing DehydraTECH, a platform technology that enhances the performance of several categories of fat-soluble active molecules and drugs across oral and/or topical formats. DehydraTECH, the company explains on its website, is an additional step that is easily and seamlessly incorporated into the formulation and manufacturing process of existing or new products.

“This step involves mixing the active ingredients as a delivery ‘payload’ together with certain fatty acids, infusing the mixture into a substrate material, and then using controlled dehydration synthesis processing to associate the payload and fatty acids together at a molecular level, before integrating the newly combined molecules into end-product production across a range of dosage form factors,” the website continues (https://ibn.fm/jsri8).

The result? The improved and more rapid absorption of active molecules into the bloodstream and brain tissue. This benefit, according to Lexaria, stems from the fact that DehydraTECH works symbiotically with existing physiological systems, thus enabling better bioavailability and bio-absorption. Another result is that fat-soluble molecules processed using the DehydraTECH technology become masked to oral and olfactory receptors, rendering them mostly flavorless and odorless.

Since 2014, Lexaria has undertaken multiple R&D programs covering such DehydraTECH-processed active molecules as nicotine, cannabidiol (“CBD”), and antiviral drugs (https://ibn.fm/cObdA). These initiatives have not only proven the above results to be true but also opened up additional commercialization opportunities.

“Our applied R&D is paying off in spades because we are currently in active discussions with several multi-billion dollar companies around the world, for the potential use of Lexaria’s DehydraTECH technology in their commercial product pursuits,” Bunka wrote in the annual CEO letter to shareholders published January 2023 (https://ibn.fm/FOOVZ). “It is a direct result of our positive R&D programs that, as 2023 begins, we are actively involved in several sets of ongoing discussions and due diligence proceedings with potential corporate partners with a goal of collaboration, DehydraTECH out-licensing, or other corporate relationships.”

Additionally, the company is working toward an Investigational New Drug (“IND”) application that will seek FDA’s approval to undertake Phase 1(b) registered trial evaluating DehydraTECH-CBD as a potential treatment for hypertension. The study, which will seek to uncover the safety and tolerability of the formulation, is expected to begin this year.

Lexaria’s accomplishments so far can be attributed largely to the guidance of CEO, Chairman and Director Chris Bunka, President and Director John Docherty, and the company’s board of directors with members who have decades of experience in public and private businesses.

For instance, Dr. Catherine C. Turkel, Pharm.D, Ph.D., has over 20 years’ experience as an executive in startup and mid-size pharma or biotech companies. Having previously served as Founder and CEO of Nezee Therapeutics and President and R&D Head at Novus Therapeutics, since renamed Eledon Pharmaceuticals (NASDAQ: ELDN), she has formulated registration and commercial strategic plans and spearheaded global development programs for pharmaceutical and biologic treatments from phase 1 through phase 4 (https://ibn.fm/o3FLS). Her experience will, therefore, be invaluable as Lexaria conducts its planned FDA clinical trials.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Net revenue increased 133% to $332,000 in the three months ended Dec. 31, 2022, the company reports
• Corporate highlights included expanded trial sites, enrollment for phase 2 IGC-AD1 study
• Commencement of study marks milestone in IGC’s progress toward gaining FDA approval for proprietary treatment

In a fragile economic environment, the third-quarter 2023 financial results reported by India Globalization Capital (NYSE American: IGC) are particularly remarkable. The company, which is pursuing effective treatment for Alzheimer’s patients suffering with agitation and other neuropsychiatric symptoms, released a report showing an increase in net revenue of 133% for the three-month period ending Dec. 31, 2023, and an increase in net revenue of 175% for the nine-month period ending the same day (https://ibn.fm/CtTBZ).

“Net revenue increased 133% to $332,000 in the three months ended Dec. 31, 2022, compared to $142,000 in the three months ended Dec. 31, 2021,” the company reported. “Net revenue increased 172% to $745,000 for the nine months ended Dec. 31, 2022, compared to $275,000 for the nine months ended Dec. 31, 2021, driven mainly by the company’s life-science segment, which includes, among others, natural products targeting women with premenstrual syndrome (‘PMS’), period pain and sleep disorder.”

The report also noted corporate highlights for the quarter, two of which are related to the company’s phase 2 clinical trial evaluating IGC-AD1 for agitation in dementia from Alzheimer’s disease. The report stated that the number of sites participating in the trial has expanded to a total of four — three in the United States and one in Canada — and that the trial will enroll 146 patients, with one-half of the participants receiving a placebo and the other half receiving IGC-AD1.

“The company is encouraged by the patient enrollment and interest from many of the leading research centers and has decided to increase the number of trial sites to between 10 and 12 from the originally planned four to five,” the company observed. “This will help accelerate the timeline for completion and diversify the patient demographics.” The goal of the trial, the company went on to explain, is to evaluate and establish over a six-week period the efficacy of IGC-AD1 in treating agitation in dementia from Alzheimer’s disease.

 “We are delighted with the progress made during this quarter, highlighted by the commencement of the phase 2 clinical trial for our drug candidate IGC-AD1 for the safety and efficacy of the drug on agitation in dementia due to Alzheimer’s disease,” said IGC CEO Ram Mukunda. “This represents a milestone in our progress towards gaining FDA approval for IGC-AD1, which we believe has the potential to revolutionize the treatment of Alzheimer’s disease as the first and only low-dose, natural, THC-based candidate currently undergoing FDA trials.

Moreover, our sales of natural products, which include gummies and pain relief creams, are seeing increased traction in the market,” he continued. “We’re encouraged by our third quarter results and look forward to driving continued expansion through the balance of fiscal 2023.”

IGC develops advanced cannabinoid-based formulations for treating diseases, including but not limited to Alzheimer’s disease, Parkinson’s disease, chronic pain and pet seizures. The company sells various brands of CBD-based consumer products, including Holief, which includes gummies and pain relief creams for women experiencing premenstrual syndrome and dysmenorrhea (period cramps). The company operates facilities in the United States under Good Manufacturing Practices.

For more information, visit the company’s website at www.IGCPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC

Experienced professionals, policy leaders, blockchain enthusiasts, professionals, and investors in the blockchain industry, are attending the 4th edition of Paris Blockchain Week (“PBW”) being held from March 20-24, 2023 at the Carrousel du LOUVRE in the heart of Paris’ famous palace and largest museum in the world.

Paris Blockchain Week is the top international conference devoted to professionals in the Web3 and blockchain space. This 4th edition of the Paris Blockchain Week is Europe’s leading blockchain event, covering: Web3, NFTs, decentralized finance, and metaverse, with 10,000+ attendees from across the world. It’s a great opportunity for blockchain fans to learn, share, and do business in one of the world’s most progressive places in the French Capital.

With the latest advancements in blockchain technology, businesses are staying informed about the newest progress. They need to reinforce their professional networks while merging the industry-wide ecosystem. The immersive nature of Paris Blockchain Week will ensure that PBW is a must-attend event dedicated to shaping the future of blockchain technology.

Explore New Opportunities and Build Strong Relationships

PBW offers a remarkable experience in Paris, engaging with several government, business, and regulatory stakeholders to discuss the rising and vibrant web3 ecosystem. The conference will feature some of the leading figures in the space discussing the most demanding challenges, and issues of the blockchain industry, including digital asset liquidity, traceability, digital governance, and much more.

Key blockchain industry personalities have already committed to speaking at this event on all things blockchain. 400+ speakers will share their knowledge with the audience and delve deep into the latest progresses in blockchain technology and its potential applications across different industries.   Top supporters and speakers at this influential blockchain industry event include Jean-Noël Barrot, Meta, Nicolas Julia, Sorare, Steve Huffman, Sébustien Borget, Nasdaq, Brad Garlinghouse, Reddit, Ripple and French Minister for Digital Transition & Telecommunications, Stephane Kasriel.

Attendees will get a better understanding of the potential of blockchain technology and its significance in shaping the future. The 2023 edition of Paris Blockchain Week is shaping up to be a blockchain extravaganza, featuring top-notch exhibitions, eye-opening workshops, and stimulating networking events.

To learn more, please visit https://ibn.fm/5IvCg

The EVCS & Expo event is being held on March 29-31, 2023 at the Mirage Hotel, Las Vegas. Company executives, directors, professionals, government organizations, and stakeholders of EV and allied industries, are invited to attend the event. The event focuses on important issues of financing, infrastructure, operability, and ROI for EV charging.

Exhibitors participating in the event will pitch their business ideas and showcase real solutions, novel ways of cost savings, and technological advances to infrastructure.  All commercial and government organizations can leverage the platform to gain in-depth knowledge and insights into hassles, challenges and solutions for EV charging infrastructures.

Key points of discussion at the summit:

• Find immediate implementation solutions for EV charging sites
• Learn new technologies and advances in the EV spectrum from exhibitors at the Expo
• Build networking ties and professional connections to harness the growth potential of the million-dollar industry
• Get ready for the BEV demand by collecting insights and knowledge from experts attending the summit
• Be prepared to take advantage of the opportunities available in the EV spectrum

Property owners, developers/investors, and industry representatives will discuss how EV charging is a valuable asset to the real-asset fraternity. They will also navigate and explore the scope of growth in bringing EV charging infrastructure to their residential or commercial site.

Another pivotal point covered at the summit includes how to offer seamless consumer experiences so that the customer realizes its importance and builds confidence in EV charging. Rural communities can benefit highly from electric vehicles but lack equitable charging infrastructure. Experts will also explore ways to bring the EV infrastructure to distant and rural areas, and places that can’t support charging infrastructure. The EV Charging infrastructure could prove extremely valuable to such areas owing to the current gas prices and considerably long daily commutes.

EVs and microgrids can serve as powerful tools in the event of a natural disaster. While EVs can be used as backup batteries, mobile charging stations can draw from utility power and battery-stored energy for quick deployment in sites inflicted with disasters. Industry leaders and veterans will speak about microgrids and EVs as temporary power solutions separate from the larger power grid.

Apart from the above, discussions will be held on investment, funding, OEM manufacturing, EV fleets, hardware & software aspects, and more.

To learn more, please visit (https://ibn.fm/n0IBn).

• A recent report published by the IEA revealed that global carbon emissions rose by 0.9% YoY in 2022, hitting a record 36.8 gigatons
• With households accounting for 30% of global greenhouse gas emissions, GeoSolar Technologies has focused on building out renewable energy solutions for homes
• U.S. households have been slow to adopt renewable energy. As of 2020, only 3.7% of U.S. households derived their electricity from solar energy versus nearly 33% in Australia
• The recently passed Inflation Reduction Act (“IRA”) in the U.S. will seek to augment that figure in the U.S., with homeowners able to benefit from an array of tax credits and rebates on any purchases of energy efficient technology

Global carbon emissions hit a new record in 2022 according to a newly published report by the International Energy Agency (“IEA”), with emissions of the greenhouse gas rising by 0.9 percent year-over-year to 36.8 gigatons – the physical equivalent of 3.6 million fully loaded aircraft carriers (https://ibn.fm/pz1e9). What makes the statistic even more remarkable is the context under which it was achieved. China emits 27 percent of the world’s carbon dioxide output and accounts for upwards of a third of global greenhouse gas emissions, yet for much of the past year, the nation’s economy has found itself at a virtual standstill – a byproduct of the Chinese government’s stringent Zero Covid policies. Accordingly, the publication of the IEA’s report has been met with some consternation by the global scientific community.

“Any emissions growth — even 1% — is a failure,” said Rob Jackson, a professor of earth system science at Stanford University and chairman of the Global Carbon Project, an international group. “We can’t afford growth. We can’t afford stasis. It’s cuts or chaos for the planet. Any year with higher coal emissions is a bad year for our health and for the Earth.”

GeoSolar Technologies (“GST”), a Colorado-based climate technology company pioneering an approach into clean energy solutions for households, has centered their corporate mission around reducing household carbon emissions – a critical objective in terms of achieving global Net Zero ambitions. Through the introduction of its proprietary SmartGreen™ Home system, an environmentally friendly, renewable energy focused technology designed to harness energy from the earth and sun to power and purify homes and automobiles without the use of fossil fuels, GeoSolar have looked to tackle the astounding thirty percent of global greenhouse gases generated by households every year. Moreover, and during a time of increasingly elevated electricity costs, the Company revealed that the average GeoSolar-powered home could result in a negligible carbon footprint with homeowners disbursing less than $100 per annum in utility bills (https://ibn.fm/MTMOg).

Nonetheless and despite GeoSolar Technologies’ ambitions, green energy adoption amongst U.S. households has been slow to take off. As of 2020, only 3.7% of U.S. homes generated electricity from renewable power sources – predominantly, small-scale solar arrays (https://ibn.fm/3cwkc). That is a marked difference relative to other parts of the world. In Australia, nearly one in three Australian households boasts solar panels – the highest penetration rate in the world. In fact, and if one were to combine Australian household solar capacity with the nation’s 11GW of large-scale solar plants, solar energy would already be classed as Australia’s largest fuel source for electrical power – a remarkable feat for a country possessing 15% of the globe’s thermal coal deposits. Nevertheless, this was not always the case. It took approximately 10 years for Australia’s households to reach their first 10GW of solar energy generation capacity; by comparison, the second 10GW of installed capacity took a mere four years.

GeoSolar Technologies has positioned itself to capitalize on a similar trend in the United States, an ambition supported by the U.S. Government’s recent policy initiatives. Under the newly passed Inflation Reduction Act, which has come into effect at the start of the year, consumers and homeowners are able to benefit from an array of rebates and tax credits towards their purchase of energy-efficient items, including appliances, electric vehicles and solar panels. In fact, homeowners could be eligible for rebates amounting to as much as $14,000 for the purchase of energy-efficient items, with the largest credits and rebates available for heat pumps, a high-efficiency system that heats and cools homes in place of conventional furnaces or air conditioners (https://ibn.fm/5HGNL).

The act has already started to have a dramatic effect, both on solar energy installations as well as on the adoption of green energy home solutions, such as the ones offered by GeoSolar Technologies. Solar accounted for 45% of all new electricity-generating capacity added to the U.S. grid through the third quarter of 2022, more than any other electricity source (https://ibn.fm/kfPiP). With the U.S. at the cusp of a household-focused green energy revolution, GeoSolar Technologies looks well-positioned to capitalize on the growing trend.

For more information, visit the company’s website at www.GeoSolarPlus.com.

NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• Boston Consulting Group estimates the near-term total addressable market (“TAM”) for quantum hardware, software and service providers, to be $400 million to $1 billion within the next three to five years
• Annealing technology represents near-term quantum tech that is solving enterprise optimization problems today for key industries
• D-Wave’s quantum computing systems and services are exploring and addressing computationally complex problems, including supply chain optimization, fraud detection, and employee scheduling

New trends in technology are creating high demand for solutions that can solve increasingly computationally complex problems. That, coupled with accelerated adoption of artificial intelligence and machine learning, are some of the main factors currently driving quantum computing market growth. Boston Consulting Group estimates the near-term TAM for quantum hardware, software and service providers, to be $400 million to $1 billion within the next three to five years.

Various industries, including healthcare, finance, logistics, and more, are turning to quantum technology to help unlock operational efficiencies and are expected to fuel this growth. Quantum computing can potentially solve problems in these sectors that are unsolvable using current methods.

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems and services, is focused on delivering customer value through practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection, and financial modeling. The company is building technologies today to enable new solutions for tomorrow – unlocking commercial use cases in optimization illustrated through its customer success stories (https://ibn.fm/3Gzqf).

When SavantX was looking to tackle supply chain problems at the Port of Los Angeles, the busiest port in the U.S. with the equivalent of over 10 million 20-foot containers transitioning the port in 2021, the company leveraged D-Wave’s quantum solutions for assistance. SavantX utilized D-Wave’s quantum technology to develop the Hyper-Optimized Nodal Efficiency Engine (HONE) framework to streamline operations at Pier 300 – one of the port’s largest terminals. HONE helped optimize the pier’s operations significantly, which led to a 50% increase in daily deliveries per crane, lowering the wait times for cargo trucks picking up payloads.

D-Wave’s customer success stories provide firsthand experiences of how the company’s quantum applications benefit industries, solving problems and illustrating the value quantum has brought to multiple sectors. The company’s extensive IP portfolio features over 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals. D-Wave’s list of commercial customers includes blue-chip industry leaders like Mastercard, Deloitte, Volkswagen, ArcelorMittal, BASF, Unisys, BBVA, NEC Corporation, Pattison Food Group, DENSO, and Lockheed Martin.

Through a real-time quantum cloud service and a team of professional services professionals to assist with problem identification and solution creation, D-Wave has made it easy for organizations to get started on their quantum journey today. Now, companies can quickly bring quantum computing into their overall compute infrastructure and start taking advantage of the benefits it could bring to their organization.

For more information, visit the company’s website at www.DWavesys.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which statements are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. We caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, which are subject to a number of risks. Forward-looking statements in this article include, but are not limited to, statements regarding the TAM for quantum hardware, software and service providers and the potential for quantum computing’s problem-solving ability. We cannot assure you that the forward-looking statements in this article will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including general economic conditions and other risks; customer acceptance of our products and services; and the uncertainties and factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the registration statement on Form S-1 filed by the Company with the SEC on February 13, 2023, as well as factors associated with companies, such as D-Wave, that are engaged in the business of quantum computing, including anticipated trends, growth rates, and challenges in those businesses and in the markets in which they operate; the outcome of any legal proceedings that may be instituted against us; risks related to the performance of our business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and or timing thereof; the performance of our products; the effects of competition on our business; the risk that we will need to raise additional capital to execute our business plan, which may not be available on acceptable terms or at all; the risk that we may never achieve or sustain profitability; the risk that we are unable to secure or protect our intellectual property; volatility in the price of our securities; the risk that our securities will not maintain the listing on the NYSE; changes in applicable laws and regulations; the effect of pandemics, geopolitical events, natural disasters, wars, or terrorist acts on our business or the economy in general; and the impact of inflation. Furthermore, if the forward-looking statements contained in this article prove to be inaccurate, the inaccuracy may be material. In addition, you are cautioned that past performance may not be indicative of future results. In light of the significant uncertainties in these forward-looking statements, you should not place undue reliance on these statements in making an investment decision or regard these statements as a representation or warranty by any person we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this article represent our views as of the date of this article. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this article.

• New data show rising burden of most cardiovascular risk factors among young adults aged 20 to 44 in the U.S.
• Findings are “extremely concerning” as expert notes “we’re witnessing a smoldering public health crisis”
• HeartBeam has developed the first and only 3D-vector electrocardiogram for heart attack detection anytime, anywhere

A recent study shows that risk factors for cardiovascular (“CV”) disease are rising among young adults (https://ibn.fm/jvjFN). Studies like this that provide critical information regarding CV disease highlight the ongoing urgency of HeartBeam’s efforts. HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector electrocardiogram for heart attack detection anytime, anywhere.

“New data show a high and rising burden of most cardiovascular risk factors among young adults aged 20 to 44 years in the United States,” states a Medscape article, reporting on study findings presented at the March 5 annual meeting of the American College of Cardiology (“ACC”). “In this age group, over the past 10 years, there has been an increase in the prevalence of diabetes and obesity, no improvement in the prevalence of hypertension, and a decrease in the prevalence of hyperlipidemia.

“Yet medical treatment rates for CV risk factors are ‘surprisingly’ low among young adults,” study investigator Rishi Wadhera, MD, with Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, told theheart.org / Medscape Cardiology.

In the article, Wadhera noted that the findings are “extremely concerning.” He stated that “we’re witnessing a smoldering public health crisis. The onset of these risk factors earlier in life is associated with a higher lifetime risk of heart disease and potentially life threatening.”

The cross-sectional study comprised 12,294 U.S. participants aged 20 to 44 who participated in National Health and Nutrition Examination Survey (“NHANES”) cycles for 2009–2010 and 2017–March 2020. The mean age of group participants was 32, and 51% of participants were women.

The article reported that, “overall, the prevalence of hypertension was 9.3% in 2009–2010 and increased to 11.5% in 2017–2020. The prevalence of diabetes rose from 3.0% to 4.1%, and the prevalence of obesity rose from 32.7% to 40.9%. The prevalence of hyperlipidemia decreased from 40.5% to 36.1%.

“Equally concerning, said Wadhera, only about 55% of young adults with hypertension were receiving antihypertensive medication, and just 1 in 2 young adults with diabetes were receiving treatment,” the article continued. “Wadhera said, ‘We need to double down on efforts to screen for and treat cardiovascular risk factors like high blood pressure and diabetes in young adults. We need to intensify clinical and public health interventions focused on primordial and primary prevention in young adults now so that we can avoid a tsunami of cardiovascular disease in the long term. It’s critically important that young adults speak with their healthcare provider about whether ― and when ― they should undergo screening for high blood pressure, diabetes, and high cholesterol.’”

Working closely with healthcare providers is a key focus of HeartBeam’s technology. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to determine quickly and easily if symptoms are due to a heart attack so care can be expedited if required.

HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack more accurately. HeartBeam AIMIGo(TM) is the first and only credit-card-sized, 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to facilitate remote heart-attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the U.S. Food and Drug Administration (“FDA”) for marketing in the United States or other geographies.

For more information, visit the company’s website at www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

• Rare earth element (“REE”) processing solutions developer Ucore Rare Metals Inc. is preparing to demonstrate the prowess of its proprietary RapidSX (TM) technological advantage as an improvement over standard REE ore separation processes
• REE production has become a matter of strategic importance to American industries and tech-based military applications, as China has built global control of vital REE markets and demonstrated a willingness to stop REE exports during international disputes
• Ucore is preparing to launch construction of a Strategic Metals Complex (“SMC”) in Louisiana later this year after demonstrating RapidSX (TM) potential at its Canadian base
• Ucore’s SMC will be the first in a series of processing facilities drawing on “allied” Western ore sources for rapid throughput of REEs to market in North America
• The company also owns an REE mine prospect in Alaska that it intends to start up once financing is secured

Tensions in an evolving tech war between the United States and China grew this month as the Netherlands announced it would agree to limit the export of “advanced” semiconductor manufacturing equipment (https://ibn.fm/aOAju) as a result of an agreement it quietly ratified with Japan and the United States in January (https://ibn.fm/W4aJe).

The export limits, which tacitly are aimed at restraining China’s world dominance in mining resources for next-generation technology used in everything from cell phones and electric vehicles to military assets, demonstrate the cooperative efforts Western governments and industries are undertaking to prevent becoming dependent on the Asian nation, whose population and economy (when measured by purchasing power parity) are the largest on earth (https://ibn.fm/P9vfJ).

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a Canadian company developing specialized rare earth element (“REE”) separation and processing solutions, is playing a role in reasserting North America’s independence in tech resource mining. The company is preparing to demonstrate its proprietary RapidSX (TM) process for the low-cost separation and purification of REEs through an accelerated form of solvent extraction at a Demonstration Plant in Ontario.

Commissioning of the Demonstration Plant is currently under way, according to a Jan. 26 Ucore statement (https://ibn.fm/eXtNB).

Ucore then intends to demonstrate its position as an REE thought leader by building a “Strategic Metals Complex” (“SMC”) processing facility in Louisiana later this year, followed by additional SMCs at sites in Alaska and Canada. The SMC processing facilities network, using Ucore’s RapidSX (TM) technology to improve on the standard SX solvent extraction process used by 100 percent of all REE producers worldwide, has the potential to help the West retain control of its supply chain for the mineral resources.

That need became particularly apparent when China leveraged its control over rare earth production to block Japan’s access to REEs in 2010 following a dispute over a dangerous fishing trawler’s detention in waters claimed by both nations (https://ibn.fm/l1n9W). Tensions between the United States and China during the Trump administration and a new Chinese threat to limit REE sourcing increased the emphasis on turning to in-country production for U.S. technologies (https://ibn.fm/sHyz6).

The Pentagon has subsequently provided millions of dollars in funding to Las Vegas-based MP Materials, which owns the Mountain Pass mine in California. Mountain Pass is currently the only operating rare earth mine and processing facility in the United States. A few other companies have been attempting to join in to help jump start large-scale U.S. production of rare earths, but the effort is time- and cost-intensive since virtually all formerly operating rare earth mines shut down on a global scale after China entered the market in the 1980s and began flooding it with low-cost REEs, independent research group Adamas Intelligence founder Ryan Castilloux stated in a Politico report on the matter (https://ibn.fm/qJHMH).

“(China) leveraged that monopoly on rare earths supply to subsequently dominate all of the value-adding steps, from mine through to metal through to magnet,” Castilloux stated.

The Politico report notes going from raw ore to magnet is an expensive, multi-step process that currently takes place across multiple continents — Mountain Pass’s ore is currently processed in China, for example. Ucore aims to employ its RapidSX (TM) processing technology and SMCs in quickly moving mined rare earths to market domestically, using “allied” rare earth feedstock derived from mines around the world, according to an Alaska Journal of Commerce report (https://ibn.fm/8ss33).

Ucore owns a rare earth mine prospect on Alaska’s Prince of Wales Island that it acquired in 2007, which it aims to ultimately develop as an additional strategic REE source for its supply chain. The mine on the Bokan Mountain-Dotson Ridge holds more than 4.7 million metric tons of indicated rare earth ore, according to a 2015 resource assessment, the Journal of Commerce report states. That translates to about 63.5 million pounds of collective rare earth metals.

Alaska’s Legislature approved up to $145 million in bonds to help finance the Bokan Mountain mine in 2014. Ucore officials state if they can obtain funding for the remainder of the mine startup, estimated at $220 million in 2013, Bokan can be “near shovel-ready” within 30 months, according to the Journal report.

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• Progressive Care reported a 4% year-over-year revenue increase to approximately $10.1 million for the quarter ended September 30, 2022
• The company’s prescription revenue increased 16% year-over-year to almost $9.4 million during that same period
• In 2022, Progressive Care received nearly $6 million from a strategic investment transaction with NextPlat Corporation
• The company launched its ClearMetrX platform for 340B third-party administration in 2022
• Progressive Care will partner with MedAvail in2023 to provide prescription dispensing kiosks

Progressive Care (OTCQB: RXMD) is a health services organization based in Florida that offers personalized healthcare services and technology that supports the managed healthcare industry. Through its subsidiaries, Progressive Care provides Third-Party Administration (“TPA”), data management and analytics, COVID-19 diagnostics and vaccinations, 340B contracted pharmacy services, compounded medications, tele-pharmacy services, dispensing of anti-retroviral medications, medication therapy management (“MTM”), long-term care facility-targeted prescription medications, and health practice risk management. The company collaborates with various healthcare organizations such as managed care organizations (“MCOs”), management services organizations (“MSOs”), accountable care organizations (“ACOs”), primary care providers, Medicare Advantage plans, Medicaid, commercial payors, pharmaceutical manufacturers, and distributors to enhance patient and provider engagement while improving the lives of patients with chronic diseases. Progressive Care offers a wide range of innovative solutions to address the dispensing, delivery, dosing, and reimbursement of clinically intensive, high-cost drugs. Progressive Care currently operates four pharmacies in Florida, which generate the majority of its revenue. Pharmacy revenue is derived from dispensing medications, third-party administrative services to 340B-covered entities, and MTM services. The company also provides customized management, patient health risk reviews, and free same- and next-day delivery. Its focus is on complex chronic diseases that require multiyear or lifelong therapy, driving recurring revenue and sustainable growth. Progressive Care’s pharmacy revenue growth stems from its expanding breadth of services, new drugs coming to market, new indications for existing drugs, volume growth with current clients, and addition of new customers resulting from its emphasis on higher patient engagement, free delivery to the patient, and clinical expertise. With licenses in 14 states, Progressive Care is poised for national expansion. The company anticipates revenue growth by signing new contract pharmacy service and data management contracts with 340B-covered entities, expanding data management and analytics services to healthcare organizations, and potential acquisitions. Subsidiaries Progressive Care’s wholly-owned subsidiaries provide services to client organizations and patients. PharmcoRx Pharmacy PharmcoRx, a full-service pharmacy, provides a complete healthcare ecosystem with services such as medication therapy management, rapid COVID-19 testing and vaccines, contactless medication delivery, Smart-Pack Unit Dosing packaging, custom compound medications, specialty medications, hospital transition pharmacy services, medication adherence monitoring, medication adherence risk management, and drug cost containment. PharmcoRx Pharmacy is a contracted pharmacy services provider for 340B-covered entities under the 340B Drug Discount Pricing Program. ClearMetrX ClearMetrX, a wholly-owned data management company, offers services that support healthcare organizations across the country. In September 2022, ClearMetrX launched the 340MetrX Platform, a software product developed by ClearMetrX that provides 340B-covered entities with data insights to effectively operate and maximize the benefits of the 340B program. 340MetrX supplies data access and delivers actionable insights that providers and support organizations can use to improve their practices and patient care. Its TPA services include management of wholesale accounts and contract pharmacies, patient eligibility with regard to the 340B drug program, development and review of 340B policies and procedures, and management of receivables. Market Opportunity According to an industry report by global consulting firm Berkeley Research Group, gross sales across the 340B drug program were valued at $116 billion in 2021 and are projected to grow to $280 billion by 2026, achieving a CAGR of more than 19% over the period. The 340B drug pricing program allows eligible healthcare clinics and hospitals (the covered entities) to purchase outpatient drugs at a 20-50 percent discount to treat low-income, uninsured, or underinsured populations. The program’s forecast growth is expected to benefit Progressive care’s business of providing 340B program services to covered entities through the nationwide expansion of ClearMetrX, its third-party administration and data-management business. Management Team Charles M. Fernandez is CEO and Chairman of the Board of Directors of Progressive Care. Mr. Fernandez is also the Executive Chairman and CEO of NextPlat Corp. (NASDAQ: NXPL) and has over 30 years of experience in identifying profitable start-up and dislocation opportunities, building significant value and executing exit strategies as an entrepreneur and global investor. In 2008, he joined Fairholme Capital Management. As president, he co-managed all three Fairholme funds and was commended for bringing in a $2 billion gain for shareholders. Throughout his impressive career in media, pharmaceuticals, healthcare, finance and technology, Mr. Fernandez has participated in more than 100 significant mergers, acquisitions and product development projects. He was the founder, chairman and CEO of eApeiron Solutions LLC, a brand protection and e-commerce company in partnership with Alibaba (NYSE: BABA) and Eastman Kodak (NYSE: KODK) which was successfully sold to Smartrac, a leading developer, manufacturer and supplier of RFID and Internet of Things (“IoT”) solutions and a unit of Avery Dennison Corporation (NYSE: AVY). Other top management team members include Chief Operating Officer Birute Norkute, Chief Financial Officer Cecile Munnik, and Pamela Roberts, who serves as the company’s Pharmacist in Charge. For more information, visit the company’s website at www.ProgressiveCareus.com. NOTE TO INVESTORS: The latest news and updates relating to RXMD are available in the company’s newsroom at https://ibn.fm/RXMD